Florida Attorney General James Uthmeier has sued the three companies that supply most of the world's insulin and the three largest pharmacy benefit managers, alleging they inflated prices paid by Florida patients. The lawsuit, announced in a statement from Uthmeier's office on Sept. 22, names Eli Lilly, Novo Nordisk, and Sanofi, along with CVS Caremark, Express Scripts, and OptumRx. The claims are allegations, and no court has ruled on them.
The state says about 2.3 million Florida adults, roughly 1 in 10, have diagnosed diabetes. Not all of them use insulin, but the complaint centers on a cost problem that can reach households across the state. People who are uninsured, still in a deductible, or paying coinsurance, a percentage of the price, are often charged based on the list price.
That detail explains why the case matters beyond the courtroom. A family that pays coinsurance on insulin may feel a high list price at the pharmacy counter every month. Some patients have rationed doses because of cost, which can lead to dangerous complications.
The Allegations at the Center of the Complaint
The complaint was filed in Florida's Eleventh Judicial Circuit, which covers Miami-Dade County. It alleges that the drugmakers raised published list prices for insulin and related diabetes drugs, then paid rebates and fees to the pharmacy benefit managers in exchange for preferred placement on the lists of drugs health plans cover. According to the state, both sides profited as sticker prices rose.
The suit also names three rebate aggregators, Zinc, Ascent, and Emisar, and covers GLP-1 and combination drugs, including Ozempic, Trulicity, Victoza, and Soliqua. It cites testimony from a Lilly executive that about $210 of every $280 Humalog vial, roughly 75%, went back to pharmacy benefit managers as rebates and discounts. Fierce Healthcare noted it was not immediately clear how recent that testimony was.
Uthmeier said the companies "inflated the sticker price of a medicine people cannot live without and left Florida patients to pay it." The state brings two counts under Florida's Deceptive and Unfair Trade Practices Act and one under the Florida Antitrust Act. It seeks a permanent injunction, restitution, disgorgement, damages, and civil penalties.
The case rests on the gap between two prices. The list price is the published sticker price, while the net price is what a manufacturer keeps after rebates. The state argues that a system built on rebates rewarded higher list prices and that patients whose costs are tied to the list price absorbed the difference.
A Legal Fight Playing Out Across the Country
Florida's case follows similar actions. The Federal Trade Commission sued the three pharmacy benefit managers and their affiliated purchasing groups in September 2024, and Fierce reported that Express Scripts and CVS have settled that case while Optum is working toward its own resolution. Delaware's attorney general filed a comparable lawsuit in the Court of Chancery in January against the same three drugmakers and three pharmacy benefit managers.
Public responses from the defendants to the Florida suit were not available in the reports MedicalDaily reviewed. In similar litigation, the companies have denied wrongdoing. Responding to an Ohio county lawsuit, Novo Nordisk said it believes the allegations against it are "meritless," according to WVXU. Sanofi said in the same case that its pricing practices have always complied with the law.
Pharmacy benefit managers and drugmakers have also blamed each other. In the Ohio case, CVS Caremark said "pharmaceutical companies alone are responsible for the prices they set," according to Spectrum News. Sanofi said rebate savings negotiated by insurers and pharmacy benefit managers are not consistently passed on to patients. Those competing explanations are likely to be tested as the Florida case moves forward.
No trial date has been publicly announced, and cases of this size often take years to resolve.
Florida Households Most Exposed to List Prices
The lawsuit's practical relevance differs by coverage. Medicare enrollees already pay no more than $35 for a one-month supply of each covered insulin under Medicare's insulin cost cap, and the deductible does not apply. The patients most exposed to list prices tend to be uninsured adults, workers on high-deductible plans, and people who pay coinsurance.
The case does not change anyone's price today, and it does not create a claims process for individual patients. Any restitution would depend on a court ruling or settlement, so patients do not need to take action at this stage.
The stakes also reach employers and health plans, whose premiums are shaped by drug spending. A change in how list prices and rebates work could affect what many insured families pay over time.
Patients struggling to afford insulin can ask a pharmacist about manufacturer savings programs, lower-cost unbranded or biosimilar versions, and whether their plan covers a preferred product at a lower copay. Anyone facing an insurance denial can ask a clinician about prior authorization or an appeal. Keeping receipts and plan statements helps when comparing options.
Rationing insulin is dangerous. Extreme thirst, frequent urination, nausea or vomiting, fruity-smelling breath, rapid breathing, or confusion can signal diabetic ketoacidosis, which requires emergency care. Do not reduce or skip insulin doses without speaking with a clinician.
Key Questions Answered
Who is Florida suing? Eli Lilly, Novo Nordisk, Sanofi, CVS Caremark, Express Scripts, OptumRx, and rebate aggregators Zinc, Ascent, and Emisar.
What does the lawsuit allege? The state alleges the companies inflated insulin list prices and exchanged rebates for preferred coverage placement. These claims have not been proven in court.
Will my insulin price drop because of this case? Not immediately. The lawsuit is at an early stage, and any remedy would come only through a court ruling or settlement.
Who pays the list price for insulin? Many uninsured patients, people still meeting a deductible, and those paying coinsurance are charged based on the list price.
Do Medicare patients benefit? Medicare already caps covered insulin at $35 per month, so the case's direct effect is larger for people with other coverage or none.
What should I do if I cannot afford insulin? Ask a pharmacist about savings programs and lower-cost versions. Never ration insulin, and seek emergency care for signs of ketoacidosis.
Published by Medicaldaily.com
